Pluristem selects fisher for worldwide dispatch.
Pluristem Therapeutics has selected Fisher BioServices as worldwide dispatch distributor of its off-the-shelf PLacental expanded (PLX) cells. Fisher will provide cryogenic storage and distribution of Pluristem's PLX cells for its clinical trials and preclinical sites around the world.
Pluristem is pursuing several indications for which clinical trials and preclinical studies are underway, including intermittent claudication, muscle regeneration, critical limb ischemia, Buerger's disease, and acute radiation syndrome. Other potential indications include the treatment of acute myocardial infarction, lung disease, and bone marrow disease.
"As we expand our roster of clinical trials for our PLX cell therapies for several indications, we needed a reliable leader in cell therapy distribution. Fisher BioServices was the clear choice for us because they are the world's leader in biological materials handling and have supported hundreds of clinical trials," said Zami Aberman, chairman and chief executive officer of Pluristem.